Literature DB >> 19800255

Mineralocorticoid receptors in the metabolic syndrome.

Maria-Christina Zennaro1, Massimiliano Caprio, Bruno Fève.   

Abstract

The mineralocorticoid receptor (MR) mediates aldosterone effects on salt homeostasis and blood pressure regulation. MR activation also promotes inflammation, cardiovascular remodelling and endothelial dysfunction, and affects adipose tissue differentiation and function. Some of these effects derive from MR activation by glucocorticoids. Recent epidemiological studies show that the incidence of metabolic syndrome increases across quartiles of aldosterone, implicating the MR as a central player in metabolic homeostasis, involving electrolyte, water and energy balance. This review summarizes the current understanding of MR-mediated effects in diverse tissues and the role of aldosterone as a cardiometabolic risk factor, and discusses the possible relationship between inappropriate MR activation (by both mineralocorticoids and glucocorticoids) and the development of metabolic syndrome.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19800255     DOI: 10.1016/j.tem.2009.05.006

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  22 in total

Review 1.  Cortisol dysregulation in obesity-related metabolic disorders.

Authors:  Rene Baudrand; Anand Vaidya
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2015-06       Impact factor: 3.243

2.  Topical Mineralocorticoid Receptor Blockade Limits Glucocorticoid-Induced Epidermal Atrophy in Human Skin.

Authors:  Eve Maubec; Cédric Laouénan; Lydia Deschamps; Van Tuan Nguyen; Isabelle Scheer-Senyarich; Anne-Catherine Wackenheim-Jacobs; Maud Steff; Stéphanie Duhamel; Sarah Tubiana; Nesrine Brahimi; Stéphanie Leclerc-Mercier; Béatrice Crickx; Claudine Perret; Selim Aractingi; Brigitte Escoubet; Xavier Duval; Philippe Arnaud; Frederic Jaisser; France Mentré; Nicolette Farman
Journal:  J Invest Dermatol       Date:  2015-02-10       Impact factor: 8.551

3.  Changes in serum aldosterone are associated with changes in obesity-related factors in normotensive overweight and obese young adults.

Authors:  Jennifer N Cooper; Linda Fried; Ping Tepper; Emma Barinas-Mitchell; Molly B Conroy; Rhobert W Evans; Maria Mori Brooks; Genevieve A Woodard; Kim Sutton-Tyrrell
Journal:  Hypertens Res       Date:  2013-05-09       Impact factor: 3.872

Review 4.  Familial hyperaldosteronism type III a novel case and review of literature.

Authors:  Natividad Pons Fernández; Francisca Moreno; Julia Morata; Ana Moriano; Sara León; Carmen De Mingo; Ángel Zuñiga; Fernando Calvo
Journal:  Rev Endocr Metab Disord       Date:  2019-03       Impact factor: 6.514

5.  The role of aldosteronism in causing obesity-related cardiovascular risk.

Authors:  David A Calhoun; Kumar Sharma
Journal:  Cardiol Clin       Date:  2010-08       Impact factor: 2.213

Review 6.  The multifaceted mineralocorticoid receptor.

Authors:  Elise Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Compr Physiol       Date:  2014-07       Impact factor: 9.090

7.  Regulation of corticoid and serotonin receptor brain system following early life exposure of glucocorticoids: long term implications for the neurobiology of mood.

Authors:  Delia M Vázquez; Charles R Neal; Paresh D Patel; Niko Kaciroti; Juan F López
Journal:  Psychoneuroendocrinology       Date:  2011-08-19       Impact factor: 4.905

8.  Marine natural product des-O-methyllasiodiplodin effectively lowers the blood glucose level in db/db mice via ameliorating inflammation.

Authors:  Rong Zhou; Zhong-Hui Lin; Cheng-Shi Jiang; Jing-Xu Gong; Li-Li Chen; Yue-Wei Guo; Xu Shen
Journal:  Acta Pharmacol Sin       Date:  2013-07-15       Impact factor: 6.150

9.  Chronic Corticosterone Treatment During Adolescence Has Significant Effects on Metabolism and Skeletal Development in Male C57BL6/N Mice.

Authors:  Scott A Kinlein; Ziasmin Shahanoor; Russell D Romeo; Ilia N Karatsoreos
Journal:  Endocrinology       Date:  2017-07-01       Impact factor: 4.736

10.  Preventive and chronic mineralocorticoid receptor antagonism is highly beneficial in obese SHHF rats.

Authors:  G Youcef; A Olivier; N Nicot; A Muller; C Deng; C Labat; R Fay; R-M Rodriguez-Guéant; C Leroy; F Jaisser; F Zannad; P Lacolley; L Vallar; A Pizard
Journal:  Br J Pharmacol       Date:  2016-04-26       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.